Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis
Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1999 |
|---|
| Umfang: |
2 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Infection - 1973, 27(1999) vom: Juni, Seite 355-356 |
| Übergeordnetes Werk: |
volume:27 ; year:1999 ; month:06 ; pages:355-356 ; extent:2 |
| Links: |
|---|
| Katalog-ID: |
NLEJ206773536 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ206773536 | ||
| 003 | DE-627 | ||
| 005 | 20230505190656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1999 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ206773536 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| 264 | 1 | |c 1999 | |
| 300 | |a 2 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Reichardt, P. |4 oth | |
| 700 | 1 | |a Handrick, W. |4 oth | |
| 700 | 1 | |a Linke, A. |4 oth | |
| 700 | 1 | |a Schille, R. |4 oth | |
| 700 | 1 | |a Kiess, W. |4 oth | |
| 773 | 0 | 8 | |i in |t Infection |d 1973 |g 27(1999) vom: Juni, Seite 355-356 |w (DE-627)NLEJ188985891 |w (DE-600)2006315-5 |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:1999 |g month:06 |g pages:355-356 |g extent:2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s150100050042 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 1999 |c 6 |h 355-356 |g 2 | ||
| matchkey_str |
article:14390973:1999----::ekctpnahobctpnanfvreaetpprclitzbcatetetrtopcienl |
|---|---|
| hierarchy_sort_str |
1999 |
| publishDate |
1999 |
| allfields |
(DE-627)NLEJ206773536 DE-627 ger DE-627 rakwb eng Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis 1999 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. Springer Online Journal Archives 1860-2002 Reichardt, P. oth Handrick, W. oth Linke, A. oth Schille, R. oth Kiess, W. oth in Infection 1973 27(1999) vom: Juni, Seite 355-356 (DE-627)NLEJ188985891 (DE-600)2006315-5 1439-0973 nnns volume:27 year:1999 month:06 pages:355-356 extent:2 http://dx.doi.org/10.1007/s150100050042 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 27 1999 6 355-356 2 |
| spelling |
(DE-627)NLEJ206773536 DE-627 ger DE-627 rakwb eng Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis 1999 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. Springer Online Journal Archives 1860-2002 Reichardt, P. oth Handrick, W. oth Linke, A. oth Schille, R. oth Kiess, W. oth in Infection 1973 27(1999) vom: Juni, Seite 355-356 (DE-627)NLEJ188985891 (DE-600)2006315-5 1439-0973 nnns volume:27 year:1999 month:06 pages:355-356 extent:2 http://dx.doi.org/10.1007/s150100050042 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 27 1999 6 355-356 2 |
| allfields_unstemmed |
(DE-627)NLEJ206773536 DE-627 ger DE-627 rakwb eng Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis 1999 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. Springer Online Journal Archives 1860-2002 Reichardt, P. oth Handrick, W. oth Linke, A. oth Schille, R. oth Kiess, W. oth in Infection 1973 27(1999) vom: Juni, Seite 355-356 (DE-627)NLEJ188985891 (DE-600)2006315-5 1439-0973 nnns volume:27 year:1999 month:06 pages:355-356 extent:2 http://dx.doi.org/10.1007/s150100050042 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 27 1999 6 355-356 2 |
| allfieldsGer |
(DE-627)NLEJ206773536 DE-627 ger DE-627 rakwb eng Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis 1999 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. Springer Online Journal Archives 1860-2002 Reichardt, P. oth Handrick, W. oth Linke, A. oth Schille, R. oth Kiess, W. oth in Infection 1973 27(1999) vom: Juni, Seite 355-356 (DE-627)NLEJ188985891 (DE-600)2006315-5 1439-0973 nnns volume:27 year:1999 month:06 pages:355-356 extent:2 http://dx.doi.org/10.1007/s150100050042 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 27 1999 6 355-356 2 |
| allfieldsSound |
(DE-627)NLEJ206773536 DE-627 ger DE-627 rakwb eng Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis 1999 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. Springer Online Journal Archives 1860-2002 Reichardt, P. oth Handrick, W. oth Linke, A. oth Schille, R. oth Kiess, W. oth in Infection 1973 27(1999) vom: Juni, Seite 355-356 (DE-627)NLEJ188985891 (DE-600)2006315-5 1439-0973 nnns volume:27 year:1999 month:06 pages:355-356 extent:2 http://dx.doi.org/10.1007/s150100050042 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 27 1999 6 355-356 2 |
| language |
English |
| source |
in Infection 27(1999) vom: Juni, Seite 355-356 volume:27 year:1999 month:06 pages:355-356 extent:2 |
| sourceStr |
in Infection 27(1999) vom: Juni, Seite 355-356 volume:27 year:1999 month:06 pages:355-356 extent:2 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Infection |
| authorswithroles_txt_mv |
Reichardt, P. @@oth@@ Handrick, W. @@oth@@ Linke, A. @@oth@@ Schille, R. @@oth@@ Kiess, W. @@oth@@ |
| publishDateDaySort_date |
1999-06-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188985891 |
| id |
NLEJ206773536 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ206773536</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190656.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ206773536</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reichardt, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Handrick, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Linke, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schille, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kiess, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Infection</subfield><subfield code="d">1973</subfield><subfield code="g">27(1999) vom: Juni, Seite 355-356</subfield><subfield code="w">(DE-627)NLEJ188985891</subfield><subfield code="w">(DE-600)2006315-5</subfield><subfield code="x">1439-0973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:27</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:355-356</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s150100050042</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">27</subfield><subfield code="j">1999</subfield><subfield code="c">6</subfield><subfield code="h">355-356</subfield><subfield code="g">2</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188985891 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1439-0973 |
| topic_title |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p r pr w h wh a l al r s rs w k wk |
| hierarchy_parent_title |
Infection |
| hierarchy_parent_id |
NLEJ188985891 |
| hierarchy_top_title |
Infection |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188985891 (DE-600)2006315-5 |
| title |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| spellingShingle |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| ctrlnum |
(DE-627)NLEJ206773536 |
| title_full |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| journal |
Infection |
| journalStr |
Infection |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1999 |
| contenttype_str_mv |
zzz |
| container_start_page |
355 |
| container_volume |
27 |
| physical |
2 |
| format_se |
Elektronische Aufsätze |
| title_sort |
leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment – a retrospective analysis in 38 children with cytic fibrosis |
| title_auth |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| abstract |
Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. |
| abstractGer |
Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. |
| abstract_unstemmed |
Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis |
| url |
http://dx.doi.org/10.1007/s150100050042 |
| remote_bool |
true |
| author2 |
Reichardt, P. Handrick, W. Linke, A. Schille, R. Kiess, W. |
| author2Str |
Reichardt, P. Handrick, W. Linke, A. Schille, R. Kiess, W. |
| ppnlink |
NLEJ188985891 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| up_date |
2024-07-06T07:51:04.167Z |
| _version_ |
1803815238152224768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ206773536</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190656.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ206773536</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment – A Retrospective Analysis in 38 Children with Cytic Fibrosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam (PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5 days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized. We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reichardt, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Handrick, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Linke, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schille, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kiess, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Infection</subfield><subfield code="d">1973</subfield><subfield code="g">27(1999) vom: Juni, Seite 355-356</subfield><subfield code="w">(DE-627)NLEJ188985891</subfield><subfield code="w">(DE-600)2006315-5</subfield><subfield code="x">1439-0973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:27</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:355-356</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s150100050042</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">27</subfield><subfield code="j">1999</subfield><subfield code="c">6</subfield><subfield code="h">355-356</subfield><subfield code="g">2</subfield></datafield></record></collection>
|
| score |
7.398945 |